Trial Profile
A Randomized, Placebo-Controlled, Pilot Crossover Study to Evaluate the Effect of Amifampridine Phosphate (3,4-Diaminopyridine Phosphate) in Patients with MuSK Antibody Positive Myasthenia Gravis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2022
Price :
$35
*
At a glance
- Drugs Amifampridine (Primary)
- Indications Myasthenia gravis
- Focus Adverse reactions; Registrational
- 10 Mar 2022 Status changed from recruiting to discontinued.
- 15 Mar 2021 According to a Catalyst Pharmaceuticals media release, study hypotheses and a revised protocol from this study will be presented to the FDA for discussion during the first half of 2021.
- 04 Jan 2019 Results presented in the Catalyst Pharmaceuticals media release.